(Alliance News) - GSK predicted an annual outturn at the top end of guidance, BAE Systems maintained its outlook, while Aston Martin softened its profit forecast. Here is what you need to know before ...

Wall Street shares last night weakened, with the S&P 500 index down 0.3% ahead of tonight’s interest rate decision and latest batch of megacap earnings. The Dow Jones Industrial Average also fell 0.5% ...

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 7.8% in the morning session after the ...

Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to profitability. See more on TEM stock.

Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...

Actuate Therapeutics' elraglusib shows promise in metastatic pancreatic cancer. Upcoming FDA meeting may accelerate approval.

The FTSE 100 has ticked up this morning after what became a wobbly session on Monday, with a stack of fresh earnings updates helping traders early on Tuesday. Entain and Games Workshop are leading ...

We expect Moderna MRNA to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0452 ET – Philips’s strong quarterly results and guidance raise ...

Its second-quarter sales rose to 7.99 billion pounds from 7.88 billion pounds in the same period the year prior.

GSK said on Wednesday it expects to report annual sales and profit towards the top end of its forecast range, after the ...

SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...